Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2012

View Archived Issues

New phosphodiesterase 10A inhibitors discovered

Phase II trial of CTP-499 advances

FluoroPharma Medical plans phase II study of cardiac imaging agent

Icatibant acetate may improve acquired angioedema

New chemokine CCR8 receptor antagonists identified at AstraZeneca

Novel kinase inhibitors developed in Spain

Roche patents new candidate hepatitis C therapies

New renin inhibitors designed in China

Collaborating companies in Japan synthetize novel CKI inhibitors

Advinus Therapeutics announces novel glucokinase activators

Seglin OGA inhibitors show promise in vivo

Madrigal launches new phase I trial of cholesterol-lowering agent

EyeGate Pharma begins phase I trial in anterior scleritis

FDA supports initiation of pivotal DSC-127 trials

EMA grants orphan drug status to Cytokinetics drug in ALS

New Taisho drug has promising pharmacological profile

Novel SYK inhibitor shows potential as asthma therapeutic

Miraculins provides details on FDA's clearance of cholesterol test

Eisai receives complete response letter on Dacogen

Stem cell product set to be assessed in patients with artery disease

FDA approves Surfaxin

AcelRx advances patient-controlled analgesia system to phase III

More encouraging results reported on levomilnacipran in MDD

Michael J. Fox Foundation awards funding to QR Pharma

Abbott to develop companion diagnostic for Merck & Co. anticancer candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...